Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...
TipRanks on MSN
Recursion Pharmaceuticals Announces New CEO Appointment
Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...
Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...
Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...
Your browser does not support the audio element. “Of all ideas I have introduced to children, recursion stands out as the one idea that is particularly able to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback